Trinity College Dublin: Researchers launch world class trials infrastructure to tackle the rapidly increasing impact of dementia

Professor Iracema Leroi, Discipline of Psychiatry, School of Medicine and the Global Brain Health Institute (GBHI), Trinity College, has been announced today as a one of six recipients of the Health Research Board (HRB)’s Clinical Research Network Awards.

The fund will allow Professor Iracema and a team of researchers at Trinity College including co-lead Professor Sean Kennelly from Tallaght University Hospital, to launch Dementia Trials Ireland (DTI). DTI will be a world-class clinical trials’ infrastructure to support and grow dementia intervention studies for the >150,000 people with/at risk of dementia in Ireland.

There are currently 64,000 people with dementia in Ireland, with this number predicted to double by 2046.

Currently, < 0.5% of people with dementia participate in research in Ireland, despite the need for evidence to address the rapidly increasing impact of dementia on our aging society.

By significantly increasing Ireland’s capacity and capability to deliver dementia-related trials’, and by increasing the number of people participating in trials, DTI aims to prevent/slow progression to dementia for those at risk, and to improve quality of life for people with dementia.

Dementia Treatment Ireland (DTI) will:

Co-develop, grow & support a world-class dementia trials infrastructure
Treble Ireland’s capacity to conduct dementia trials
Support the delivery of Ireland’s strategic policies for dementia
DTI will involve a panel of research users at its core, working alongside 39 people which will include

Clinicians, clinical academics, basic neuroscientists, neural engineers, connected health specialists, methodologists and administrators.

Clinical Trials
Clinical trials are a type of research in which different types of treatments (medication or non-medication related) are tested to see whether they are helpful and do no harm. By participating in trials, people with a health condition, such as dementia, can access treatments that may not otherwise be available. Participation also allow them to contribute towards the wider goal of helping to find the best way to manage or slow down dementia. Many people find this very empowering.

Clinical trials for other types of health conditions (such as cancer) are much more available than for people with dementia, which is one of the reasons why our ability to manage/slow down dementia is lacking. We need to change this. Ireland is aging and the number of people at risk of dementia or living with dementia is rapidly increasing. Thus, researchers urgently need to find the right treatments. Clinical trials will help them do that.

Professor Leroi said:

We are thrilled to be able to launch Dementia Trials Ireland with the support of the HRB. The treatment of dementia and support for people living with the condition is a national priority. Dementia Trials Ireland will help us to address this on a national scale and bring cutting edge treatments for Alzheimer’s disease and other forms of dementia to Ireland.

It is every person’s right to access clinical research. Dementia Trials Ireland will increase the opportunities for people across Ireland to access research, bringing new opportunities for treatment to Ireland. We intend to address brain health challenges all the way from the pre-dementia stage for people ‘at risk’ of dementia to people living with advanced dementia in nursing homes.